Loading stock data…
TYRA
$34.04-0.71 (-2.04%)
Pre-Market$34.39+0.35 (+1.03%)· Last close May 1
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tyra Biosciences, Inc. in the Healthcare sector is trading at $34.04. The stock is currently 16% below its 52-week high of $40.65, remaining 49.1% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why TYRA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$34.04
Potential Upside
5%
Whystock Fair Value$35.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$51.24+50.5%
Range$37.00 – $59.62
Fundamentals
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.22B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.83%
Volume
Today's trading volume
741,073
Recent News
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Tyra Biosciences, Inc. is one of the best biotech stocks on this list. TheFly reported on April 15 that Guggenheim Securities initiated coverage of TYRA with a Buy rating and set a price target of $54. The firm highlighted […]
A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress
Tyra Biosciences (TYRA) has drawn fresh attention after arranging a US$126 million stock sale to a large investment firm, together with progress on late stage trials and recent leadership changes. See our latest analysis for Tyra Biosciences. Those headlines have arrived during a strong run for the stock, with a 47.85% year to date share price return and a very large 1 year total shareholder return that points to strong momentum rather than fading enthusiasm. If Tyra’s surge has you thinking...
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.